← Back to Clinical Trials
Recruiting NCT06681506

NCT06681506 A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06681506
Status Recruiting
Phase
Sponsor Shanghai 10th People's Hospital
Condition Ischemic Heart Disease
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-01-01
Primary Completion 2028-12-31

Trial Parameters

Condition Ischemic Heart Disease
Sponsor Shanghai 10th People's Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age 85 Years
Start Date 2024-01-01
Completion 2028-12-31
Interventions
Metronomic breathing, exercise rehabilitation, external counterpulsation, extracorporeal shock wave.bedside rehabilitation and breathing, balance, flexibility, movement rehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Cardiac rehabilitation is an important link in cardiovascular disease. This study mainly explores the effectiveness of new cardiac rehabilitation therapy (early respiratory rehabilitation, phase I rehabilitation, exercise therapy, external counterpulsation, extracorporeal shock wave, etc.) on patients with ischemic heart disease such as coronary heart disease and heart failure, and the compliance of home rehabilitation compared with traditional cardiac rehabilitation therapy (traditional exercise rehabilitation, rehabilitation education, etc.).

Eligibility Criteria

Inclusion Criteria: * Aged between 18 and 85 years old * Female subjects no pregnancy * The main admission diagnosis of ischemic heart disease (coronary heart disease, myocardial infarction, ischemic heart failure, etc.) * The need for cardiac rehabilitation treatment Exclusion Criteria: * acute respiratory distress syndrome (ARDS); * acute episode of COPD; * uncontrolled pulmonary infection; * acute heart failure; acute pulmonary embolism; * acute myocarditis/pericarditis; * severe arrhythmia (degree II or III atrioventricular block, atrial flutter, or atrial fibrillation); * sternotomy, rib fracture, thoracic deformity, or other neurological diseases that may affect respiratory muscles

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology